Millipore Sigma Vibrant Logo

474791 InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem

InSolution™ MG-132, CAS 133407-82-6, is provided as a 10 mM solution in DMSO. Acts as a potent, reversible proteasome inhibitor (Ki = 4 nM).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: Z-LLL-CHO, Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Proteasome Inhibitor XI

Primary Target: proteasome
View Products on Sigmaaldrich.com
474791
查看价格及供货情况

概述

Replacement Information

重要规格表

CAS #Empirical Formula
133407-82-6C₂₆H₄₁N₃O₅

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
474791-1MGCN
正在查询供货情况......
—
目前缺货 目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余：另行通知
      其余：另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      		 塑胶安瓿;塑胶针药瓶 1 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      —
      Request Pricing
      		 —
      474791-5MGCN
      正在查询供货情况......
      —
      目前缺货 目前缺货
      有货 
      停产
      少量现货
      供货情况有待确认
        其余：另行通知
          其余：另行通知
          另行通知
          联系客户服务
          Contact Customer Service

          		 塑胶安瓿;塑胶针药瓶 5 mg
          正在检索价格......
          无法检索价格。
          最小订购数量为倍数
          Maximum Quantity is
          以订单确认为准 更多信息
          您节约了 ()。
           
          —
          Request Pricing
          		 —
          Description
          Catalogue Number474791
          Brand Family Calbiochem®
          SynonymsZ-LLL-CHO, Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Proteasome Inhibitor XI
          References
          ReferencesMeriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
          Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
          Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
          Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
          Read, M.A., et al. 1995. Immunity 2, 493.
          Rock, K.L., et al. 1994. Cell 78, 761.
          Product Information
          CAS number133407-82-6
          ATP CompetitiveN
          FormLiquid
          FormulationA 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
          Hill FormulaC₂₆H₄₁N₃O₅
          Chemical formulaC₂₆H₄₁N₃O₅
          ReversibleY
          Quality LevelMQ100
          Applications
          Biological Information
          Primary Targetproteasome
          Primary Target IC<sub>50</sub>3 µM in inhibiting NF-κB activation
          Primary Target K<sub>i</sub>4 nM as proteasome inhibitor
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 36/38

          Irritating to eyes and skin.
          S PhraseS: 26-36-45

          In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
          Wear suitable protective clothing.
          In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Blue Ice Only
          Toxicity Irritant
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications
          Global Trade Item Number
          产品目录编号 GTIN
          474791-1MGCN 04055977185515
          474791-5MGCN 04055977185522

          Documentation

          InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem MSDS

          职位

          物料安全数据表 (MSDS) 

          InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem 分析证书

          标题批号
          474791

          参考

          参考信息概述
          Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
          Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
          Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
          Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
          Read, M.A., et al. 1995. Immunity 2, 493.
          Rock, K.L., et al. 1994. Cell 78, 761.

          小册子

          标题
          Caspases and other Apoptosis Related Tools Brochure

          引用

          标题
        • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
        • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
        • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
        • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
        • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
        • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
        • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
        • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
        • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
        • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
          		•
          数据表

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision03-June-2013 JSW
          SynonymsZ-LLL-CHO, Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Proteasome Inhibitor XI
          DescriptionPotent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 µM).
          FormLiquid
          FormulationA 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
          Intert gas (Yes/No) Packaged under inert gas
          CAS number133407-82-6
          Chemical formulaC₂₆H₄₁N₃O₅
          Purity≥98% by HPLC
          Storage Protect from light
          -20°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
          Toxicity Irritant
          ReferencesMeriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
          Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
          Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
          Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
          Read, M.A., et al. 1995. Immunity 2, 493.
          Rock, K.L., et al. 1994. Cell 78, 761.
          Citation
        • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
        • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
        • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
        • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
        • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
        • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
        • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
        • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
        • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
        • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
          		•